Navigation Links
KV Pharmaceutical Announces Stockholder Action to Amend By-Laws is Invalid
Date:8/7/2009

future events and trends.

All statements that address expectations or projections about the future, including without limitation, product development, product launches, regulatory approvals, market position, acquisitions, sale of assets, revenues, expenditures, resumption of manufacturing and distribution of products and the impact of the recall and suspension of shipments on revenues, and other financial results, are forward-looking statements.

All forward-looking statements are based on current expectations and are subject to risk and uncertainties. In connection with the "safe harbor" provisions, the Company provides the following cautionary statements identifying important economic, political and technological factors, which among others, could cause actual results or events to differ materially from those set forth or implied by the forward-looking statements and related assumptions.

Such factors include (but are not limited to) the following: (1) the ability to continue as a going concern; (2) changes in the current and future business environment, including interest rates and capital and consumer spending; (3) the difficulty of predicting FDA approvals, including timing, and that any period of exclusivity may not be realized; (4) the possibility of not obtaining FDA approvals or delay in obtaining FDA approvals; (5) acceptance and demand for new pharmaceutical products; (6) the introduction and impact of competitive products and pricing, including as a result of so-called authorized-generic drugs; (7) new product development and launch, including the possibility that any product launch may be delayed or that product acceptance may be less than anticipated; (8) reliance on key strategic alliances; (9) the availability of raw materials and/or products manufactured for the Company under contract manufacturing arrangements with third parties; (10) the regulatory environment, including regulatory agency an
'/>"/>

SOURCE KV Pharmaceutical Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results
2. Onyx Pharmaceuticals Announces Pricing of Concurrent Offerings of Four Million Shares of Common Stock and $200 Million Principal Amount of Convertible Senior Notes
3. Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009
4. Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals Lead Antibody
5. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
6. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
7. Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results
8. ADVENTRX Pharmaceuticals Announces Financing
9. Idenix Pharmaceuticals Prices Underwritten Offering of Common Stock
10. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
11. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... , April 30, 2015 The following is an ... Directors of China Cord Blood Corp (NYSE: CO ) ... committee of the independent directors of China Cord Blood Corp ... offer of $6.40 per share from Golden Meditech Holdings Co ... per share would greatly benefit Golden Med and Mr. Kam, ...
(Date:4/30/2015)... DUBLIN , April 30, 2015 ... a Leading Global Biotechnology Company   ... results for the three months to March 31, 2015. ... Product sales $1,423 million +9% +13% Total revenues $1,488 ... +16% +19% US GAAP operating income from continuing operations ...
(Date:4/30/2015)... Clinovo Staffing Solutions will represent Clinovo ... in Orlando, FL on May 17-20th, 2015. Trisha Heredia, ... Manager of Staffing Solutions, will present Clinovo’s staffing services ... , “We are excited to be participating in ... Heredia, Senior Director of Staffing Solutions at Clinovo. “PharmaSUG ...
(Date:4/29/2015)... , April 29, 2015   Doximity , ... of all US doctors as members, announced a new, ... — "Apply Using Doximity." With one click, all US ... a curriculum vitae (CV) for an open job opportunity, ... directly. Eighty seven percent of physicians are ...
Breaking Biology Technology:April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 2April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 3April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 4April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 5Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 2Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 3Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 4Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 5Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 6Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 7Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 8Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 9Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 10Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 11Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 12Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 13Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 14Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 15Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 16Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 17Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 18Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 19Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 20Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 21Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 22Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 23Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 24Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 25Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 26Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 27Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 28Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 29Clinovo Exhibits at the 2015 PharmaSUG Annual Conference on May 17-20th in Orlando, FL 2Clinovo Exhibits at the 2015 PharmaSUG Annual Conference on May 17-20th in Orlando, FL 3Doximity Offering Hospitals Easy, Efficient Physician Application Tool 2
... investment in science and technology, as well expand ... third Office of Naval Research (ONR)-sponsored International Lecture ... headquarters. "The Arrival of Brazil" lecture featured ... Warfare Center, Carderock; Dr. Eugenius Kaszkurewicz, director of ...
... Oct. 22 Shrink Nanotechnologies, Inc. ("Shrink") (OTC ... nanotechnology company developing products and licensing opportunities in ... and biotechnology research and development tools businesses, announced ... to produce a high content screening tool for ...
... Encorium Group, Inc. (Nasdaq:  ENCO), (the "Company"), ... conducting studies in over 30 countries for many ... today announced that, on October 20, 2010, it ... (the "Panel") has determined to delist the Company,s ...
Cached Biology Technology:ONR lecture focuses on Brazil's growth in global science and technology 2Shrink Nanotechnologies Enters Into Agreement to Produce High Content Screening Software Called 'Stemage' for its StemDisc Stem Cell Culturing Products 2Shrink Nanotechnologies Enters Into Agreement to Produce High Content Screening Software Called 'Stemage' for its StemDisc Stem Cell Culturing Products 3Shrink Nanotechnologies Enters Into Agreement to Produce High Content Screening Software Called 'Stemage' for its StemDisc Stem Cell Culturing Products 4Shrink Nanotechnologies Enters Into Agreement to Produce High Content Screening Software Called 'Stemage' for its StemDisc Stem Cell Culturing Products 5Encorium Announces NASDAQ Panel Decision to Delist Common Stock; Announces Changes to its Board of Directors 2Encorium Announces NASDAQ Panel Decision to Delist Common Stock; Announces Changes to its Board of Directors 3Encorium Announces NASDAQ Panel Decision to Delist Common Stock; Announces Changes to its Board of Directors 4
(Date:4/2/2015)... , April 2, 2015 ... tests DERMALOG by far outperforms the strongest competitors, ... maintaining high accuracy, the system is capable of ... the speed proves up to be ten times ... than its runner-up performance.      (Photo: ...
(Date:4/1/2015)... 1, 2015   Medisafe ™, the leading global ... iOS and Android smartphones and ... into the platform to allow patients to track and ... first time, patients will be able to visualize in ... important biometrics, such as glucose levels and blood pressure. ...
(Date:3/24/2015)... and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has announced ... 2015-2019" report to their offering. The ... at a CAGR of 23.5 percent over the period ... and the growth prospects of the Global Iris Recognition ... size, the report considers the revenue generated from sales ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... has termed the "World Series of Science," featuring topics ranging ... convicted of murder to a spray-on coating to keep America,s ... WHERE: The Pennsylvania Convention Center and downtown ... 2012 WHY: To join an estimated 14,000 ...
... Elsevier, a world-leading provider of scientific, technical and medical ... Applied and Translational Genomics , an open access journal. ... genomics and translational research. The completion of ... takes the genetic code and applies it to research ...
... MAA research team led by Xian Chang Li, MD, PhD, ... light on how a population of lymphocytes, called CD4+ T ... In particular, the team uncovered that a particular cell surface ... T helper cells that make copious amounts of interleukin-9 (IL-9) ...
Cached Biology News:Press accreditation for 'World Series of Science' 2Cell receptor has proclivity for T helper 9 cells, airway inflammation 2
Extra Large bottle for hybridization 300 x 70mm...
Request Info...
... The Thermo IEC Microtube Rotor is ... have to change rotors. You can ... and PCR tubes. Exclusive polypropylene rotor design ... repeatedly autoclaved. Polypropylene rotors are fully ...
... Wellpro 384, compatible with ... liquid handling system for ... and accurately prepares large ... The Wellpro also ...
Biology Products: